Eikon Posts $86.1M Q3 Loss, Cash Runway Extended Into Q1 2028
EIKN sits 33% above its 52-week low of $5.01.
Summary
Eikon reported a Q3 2026 net loss of $86.1 million, or $1.59 a share, wider than the $71.1 million loss a year earlier, as R&D spending rose 21% to $71.8 million. It ended September with $461.7 million in cash and marketable securities and now expects that to fund operations into the first quarter of 2028, covering the key 2027 readouts. The clinical update largely recaps the ESMO data already disclosed in the October 23 and October 26 8-Ks, including the 63.1% ORR for EIK1001 in the pooled NSCLC population. The one genuinely new regulatory item is the October 14 IND filing for EIK1006 in metastatic prostate cancer. Next hard catalysts are the TeLuRide-006 interim analysis in the first half of 2027 and TeLuRide-008 dose selection in the second half of 2027.
At the time of this announcement, EIKN was trading at $6.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $361.3M. The 52-week trading range was $5.01 to $17.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.